NEW YORK, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into ADMA Biologics, Inc. (NASDAQ: ADMA) for potential violations of the federal securities laws. If you invested in ADMA Biologics, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/adma-biologics-inc. Why Did ADMA Biologics’s Stock Drop? ADMA Biologics is an end-to-end commercial biopharmaceutical company that manufactures, ...

RAMSEY, N.J. and BOCA RATON, Fla., Oct. 29, 2024 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) ("ADMA" or the "Company"), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty biologics, today announced that it will report third quarter 2024 financial results on November 7, 2024, after the U.S. financial markets close. ADMA's management team will host a live conference call and audio webcast on that date at 4:30 p.m. ET to discuss its fi ...

NEW YORK, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into ADMA Biologics, Inc. (NASDAQ:ADMA) for potential violations of the federal securities laws. If you invested in ADMA Biologics, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/adma-biologics-inc. Why Did ADMA Biologics’s Stock Drop? ADMA Biologics is an end-to-end commercial biopharmaceutical company that manufactures, ...

NEW YORK, Oct. 27, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into ADMA Biologics, Inc. (NASDAQ: ADMA) for potential violations of the federal securities laws. If you invested in ADMA Biologics, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/adma-biologics-inc. Why Did ADMA Biologics's Stock Drop? ADMA Biologics is an end-to-end commercial biopharmaceutical company that manufactures, ...

NEW YORK, Oct. 25, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into ADMA Biologics, Inc. (NASDAQ: ADMA) for potential violations of the federal securities laws. If you invested in ADMA Biologics, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/adma-biologics-inc. Why Did ADMA Biologics’s Stock Drop? ADMA Biologics is an end-to-end commercial biopharmaceutical company that manufactures, ...

NEW YORK, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into ADMA Biologics, Inc. (NASDAQ: ADMA) for potential violations of the federal securities laws. If you invested in ADMA Biologics, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/adma-biologics-inc. Why Did ADMA Biologics's Stock Drop? ADMA Biologics is an end-to-end commercial biopharmaceutical company that manufactures, ...

The most recent trading session ended with Adma Biologics (ADMA) standing at $15.62, reflecting a -1.01% shift from the previouse trading day's closing. The stock fell short of the S&P 500, which registered a loss of 0.18% for the day. Meanwhile, the Dow experienced a drop of 0.8%, and the technology-dominated Nasdaq saw an increase of 0.27%. Shares of the infectious disease drug developer have depreciated by 21.02% over the course of the past month, underperforming the Medical sector's loss of 3.03% and th ...

NEW YORK, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into ADMA Biologics, Inc. (NASDAQ: ADMA) for potential violations of the federal securities laws. If you invested in ADMA Biologics, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/adma-biologics-inc. Why Did ADMA Biologics’s Stock Drop? ADMA Biologics is an end-to-end commercial biopharmaceutical company that manufactures, ...

Core Points - ADMA Biologics, Inc. is under investigation for potential violations of federal securities laws following the unexpected resignation of its independent auditor, CohnReznick LLP [1] - The stock price of ADMA Biologics dropped over 20% during trading on October 10, 2024, after the announcement of the auditor's resignation [1] Company Overview - ADMA Biologics is a biopharmaceutical company that specializes in manufacturing, marketing, and developing specialty biologics aimed at treating immunodeficient patients and those at risk for infectious diseases [1] Legal Context - Bleichmar Fonti & Auld LLP, a prominent law firm known for representing plaintiffs in securities class actions, is leading the investigation into ADMA Biologics [3] - The firm has a strong track record, having recovered significant amounts from other companies, including over $900 million from Tesla's Board of Directors and $420 million from Teva Pharmaceutical Industries [3]

NEW YORK, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into ADMA Biologics, Inc. (NASDAQ: ADMA) for potential violations of the federal securities laws. If you invested in ADMA Biologics, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/adma-biologics-inc. Why Did ADMA Biologics’s Stock Drop? ADMA Biologics is an end-to-end commercial biopharmaceutical company that manufactures, ...